Image

    Spironolactone Use Does Not Increase the Risk of Female Breast Cancer Recurrence: A Retrospective Analysis

    May 2020 in “ Journal of The American Academy of Dermatology ”
    Chapman Wei, Patawut Bovonratwet, Alex Gu … Adam Friedman
    Studysummary This study found that spironolactone was not independently associated with increased breast cancer recurrence and may be considered for treating alopecia in survivors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies Breast Cancer Research and Treatment · 2018
    2. Permanent Scalp Alopecia Related to Breast Cancer Chemotherapy by Sequential Fluorouracil/Epirubicin/Cyclophosphamide (FEC) and Docetaxel: A Prospective Study of 20 Patients Annals of Oncology · 2012
    3. Innovative Use of Spironolactone as an Antiandrogen in the Treatment of Female Pattern Hair Loss PubMed · 2010